AIM ImmunoTech (AIM) Non Operating Interest Expenses (2010)
AIM ImmunoTech's (AIM) quarterly Non Operating Interest Expenses came in at $249000.0 in Q4 2010.
AIM ImmunoTech (AIM) Non Operating Interest Expenses (2010) Analysis & Trends
AIM ImmunoTech (AIM) has 1 years of Non Operating Interest Expenses data on file, last reported at $249000.0 in Q4 2010.
- Quarterly Non Operating Interest Expenses changed N/A year-over-year to $249000.0 in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $249000.0 (changed N/A YoY) and the FY2010 annual result came in at $249000.0, down 11.7% from the prior year.
- Non Operating Interest Expenses held at $249000.0 in Q4 2010.
- In the past five years, Non Operating Interest Expenses ranged from a high of $249000.0 in Q4 2010 to a low of $249000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 295,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 249,000.00 |